Free Trial

Caroline Palomeque Analyst Performance

Analyst at Maxim Group

Caroline Palomeque is a stock analyst at Maxim Group focused in the medical sector, covering 14 publicly traded companies. Over the past year, Caroline Palomeque has issued 1 stock ratings, including and buy recommendations. While full access to Caroline Palomeque's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Caroline Palomeque's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
82 Last 8 Years
Buy Recommendations
100.00% 82 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%82 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.9% of companies on NASDAQ
13 companies
OTCMKTS
7.1% of companies on OTCMKTS
1 company

Caroline Palomeque, an analyst at Maxim Group, currently covers 14 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
13 companies
92.9%
Consumer Cyclical
1 company
7.1%

Caroline Palomeque of Maxim Group specializes in stock coverage within the Medical sector, with additional focus on Consumer Cyclical companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
28.6%
MED - DRUGS
4 companies
28.6%
PHARMACEUTICAL PREPARATIONS
3 companies
21.4%
SURGICAL & MEDICAL INSTRUMENTS
1 company
7.1%
TRAVEL SERVICES
1 company
7.1%
MED INSTRUMENTS
1 company
7.1%

Caroline Palomeque's Ratings History at Maxim Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
9/4/2025Upgrade$2.06$8.00Buy